Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer

about

Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer

Item

http://www.wikidata.org/entity/Q57117154

description

im September 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Outcome analysis of Phase I tr ...... ant non-small cell lung cancer

@en

Outcome analysis of Phase I tr ...... ant non-small cell lung cancer

@nl

type

Item

label

Outcome analysis of Phase I tr ...... ant non-small cell lung cancer

@en

Outcome analysis of Phase I tr ...... ant non-small cell lung cancer

@nl

prefLabel

Outcome analysis of Phase I tr ...... ant non-small cell lung cancer

@en

Outcome analysis of Phase I tr ...... ant non-small cell lung cancer

@nl

P1476

Outcome analysis of Phase I tr ...... ant non-small cell lung cancer

@en

P2093

Baoen Shan

http://www.w3.org/2001/XMLSchema#string

Charles Lu

http://www.w3.org/2001/XMLSchema#string

Daniel Karp

http://www.w3.org/2001/XMLSchema#string

David Hong

http://www.w3.org/2001/XMLSchema#string

Kenneth Hess

http://www.w3.org/2001/XMLSchema#string

Naiyi Shi

http://www.w3.org/2001/XMLSchema#string

Russell Broaddus

http://www.w3.org/2001/XMLSchema#string

Siqing Fu

http://www.w3.org/2001/XMLSchema#string

Vali Papadimitrakopoulou

http://www.w3.org/2001/XMLSchema#string

Vivek Subbiah

http://www.w3.org/2001/XMLSchema#string

P2860

Amino acid substitution matrices from protein blocks

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.

Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers.

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Comprehensive genomic characterization of squamous cell lung cancers.

Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer

Ras oncogenes: split personalities

P304

33258-33270

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25947

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Apostolia Maria Tsimberidou

P577

2018-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30279957

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

6161801

http://www.w3.org/2001/XMLSchema#string